“An Mrna Vaccine Against Sars-Cov-2 - Preliminary Report.”. N Engl J Med. N Engl J Med. doi:10.1056/NEJMoa2022483.
. 2020. “Safety And Immunogenicity Of Sars-Cov-2 Mrna-1273 Vaccine In Older Adults.”. N Engl J Med. N Engl J Med. doi:10.1056/NEJMoa2028436. https://pubmed.ncbi.nlm.nih.gov/32991794/.
. 2020. “Safety And Immunogenicity Of Three Seasonal Inactivated Influenza Vaccines Among Pregnant Women And Antibody Persistence In Their Infants.”. Vaccine 38 (33). Vaccine: 5355-5363. doi:10.1016/j.vaccine.2020.05.059.
. 2020. “Antibody Responses Among Adolescent Females Receiving Two Or Three Quadrivalent Human Papillomavirus Vaccine Doses At Standard And Prolonged Intervals.”. Vaccine 36 (6). Vaccine: 881-889. doi:10.1016/j.vaccine.2017.12.042.
. 2018. “Randomized Clinical Trial Of A Single Versus A Double Dose Of 13-Valent Pneumococcal Conjugate Vaccine In Adults 55 Through 74 Years Of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine.”. Vaccine 36 (5). Vaccine: 606-614. doi:10.1016/j.vaccine.2017.12.061.
. 2018. “Randomized Trial Comparing The Safety And Antibody Responses To Live Attenuated Versus Inactivated Influenza Vaccine When Administered To Breastfeeding Women.”. Vaccine 36 (31). Vaccine: 4663-4671. doi:10.1016/j.vaccine.2018.06.036.
. 2018. “Safety And Immunogenicity Of Seasonal Trivalent Inactivated Influenza Vaccines In Pregnant Women.”. Vaccine 36 (52). Vaccine: 8054-8061. doi:10.1016/j.vaccine.2018.10.088.
. 2018. “Safety And Immunogenicity Of A Modified Vaccinia Ankara Vaccine Using Three Immunization Schedules And Two Modes Of Delivery: A Randomized Clinical Non-Inferiority Trial.”. Vaccine 35 (13). Vaccine: 1675-1682. doi:10.1016/j.vaccine.2017.02.032.
. 2017. “Comparison Of Lyophilized Versus Liquid Modified Vaccinia Ankara (Mva) Formulations And Subcutaneous Versus Intradermal Routes Of Administration In Healthy Vaccinia-Naïve Subjects.”. Vaccine 33 (39). Vaccine: 5225-34. doi:10.1016/j.vaccine.2015.06.075.
. 2015. “Effect Of Varying Doses Of A Monovalent H7N9 Influenza Vaccine With And Without As03 And Mf59 Adjuvants On Immune Response: A Randomized Clinical Trial.”. Jama 314 (3). Jama: 237-46. doi:10.1001/jama.2015.7916.
. 2015. “Safety And Immunogenicity Of A Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine In Healthy Persons ≥18 Years Old.”. J Infect Dis 212 (4). J Infect Dis: 552-61. doi:10.1093/infdis/jiv056.
. 2015. “Immunogenicity Of Avian Influenza A/anhui/01/2005(H5N1) Vaccine With Mf59 Adjuvant: A Randomized Clinical Trial.”. Jama 312 (14). Jama: 1420-8. doi:10.1001/jama.2014.12609.
. 2014. “Safety And Immunogenicity Of Tetanus Diphtheria And Acellular Pertussis (Tdap) Immunization During Pregnancy In Mothers And Infants: A Randomized Clinical Trial.”. Jama 311 (17). Jama: 1760-9. doi:10.1001/jama.2014.3633.
. 2014. “Immunogenicity And Safety Of Varying Dosages Of A Monovalent 2009 H1N1 Influenza Vaccine Given With And Without As03 Adjuvant System In Healthy Adults And Older Persons.”. J Infect Dis 206 (6). J Infect Dis: 811-20. doi:10.1093/infdis/jis427.
. 2012. “Phase 2 Assessment Of The Safety And Immunogenicity Of Two Inactivated Pandemic Monovalent H1N1 Vaccines In Adults As A Component Of The U.s. Pandemic Preparedness Plan In 2009.”. Vaccine 30 (28). Vaccine: 4240-8. doi:10.1016/j.vaccine.2012.04.044.
. 2012. “Immunogenicity Of An Inactivated Monovalent 2009 H1N1 Influenza Vaccine In Pregnant Women.”. J Infect Dis 204 (6). J Infect Dis: 854-63. doi:10.1093/infdis/jir440.
. 2011. “Safety And Immunogenicity Of Influenza A H5 Subunit Vaccines: Effect Of Vaccine Schedule And Antigenic Variant.”. J Infect Dis 203 (5). J Infect Dis: 666-73. doi:10.1093/infdis/jiq093.
. 2011.